NCT04202965View on ClinicalTrials.gov

PTG-300 in Subjects With Hereditary Hemochromatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

October 6, 2021

Study Completion Date

February 15, 2022

Conditions
Hereditary Hemochromatosis
Interventions
DRUG

PTG-300

Active treatment with PTG-300 injected subcutaneously.

Trial Locations (11)

20817

Protagonist Investigational Site, Bethesda

23226

Protagonist Investigational Site, Richmond

28210

Protagonist Investigational Site, Charlotte

30214

Protagonist Investigational Site, Fayetteville

75246

Protagonist Investigational Site, Dallas

77030

Protagonist Investigational Site, Houston

77058

Protagonist Investigational Site, Houston

77384

Protagonist Investigational Site, Conroe

98105

Protagonist Investigational Site, Seattle

Unknown

Protagonist Investigational Site, Halifax

M6H 3M1

Protagonist Investigational Site, Toronto

All Listed Sponsors
lead

Protagonist Therapeutics, Inc.

INDUSTRY

NCT04202965 - PTG-300 in Subjects With Hereditary Hemochromatosis | Biotech Hunter | Biotech Hunter